Literature DB >> 19168695

MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model.

Samuel Valable1, Dauphou Eddi, Jean-Marc Constans, Jean-Sébastien Guillamo, Myriam Bernaudin, Simon Roussel, Edwige Petit.   

Abstract

Despite treatment efforts, the median survival in patients with glioblastoma multiforme, the most aggressive form of glioma, does not extend beyond 12-15 months. One of the major pathophysiological characteristics of these tumors is their ability to induce active angiogenesis. Thus, based on the lack of efficient therapies, agents that inhibit angiogenesis are particularly attractive as a therapeutic option. However, it has been recently proposed that although specifically targeting vascular endothelial growth factor, the main angiogenic factor, certainly leads to significant tumor regression, it could also be followed by tumor relapses. In this case, angiogenesis is driven by alternate pathways that include other angiogenic factors. One possible strategy to overcome this therapeutic obstacle is to overexpress antivascular factors such as angiopoietin-2 (Ang2). Here, by using MRI and histological analysis, we studied the vascular events involved in glioma growth impairment induced by Ang2 overexpression. Our results show that an increase in Ang2 expression, during the tumor growth, leads to a significant decrease in tumor growth ( approximately 86%) along with an increase in the survival median ( approximately 70%) but does not modify the tumor vascular area or cerebral blood volume. However, tumor Ang2-derived blood vessels display an abnormal, enlarged morphology. We show that the presence of Ang2 leads to an enhancement of tumor perfusion and a decrease in tumor vessel permeability. Based on our MR image evaluations of hemodynamic tumor vessel changes, we propose that Ang2-derived tumor vessels lead to an inadequate oxygenation of the tumor tissue, leading to impairment in tumor growth.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168695      PMCID: PMC2765339          DOI: 10.1215/15228517-2008-117

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  41 in total

Review 1.  Methodology of brain perfusion imaging.

Authors:  E L Barbier; L Lamalle; M Décorps
Journal:  J Magn Reson Imaging       Date:  2001-04       Impact factor: 4.813

Review 2.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.

Authors:  Lynn Hlatky; Philip Hahnfeldt; Judah Folkman
Journal:  J Natl Cancer Inst       Date:  2002-06-19       Impact factor: 13.506

3.  Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade.

Authors:  Alan Jackson; Andrea Kassner; Deborah Annesley-Williams; Helen Reid; Xiau-Ping Zhu; Kah-Loh Li
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

4.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1.

Authors:  G Thurston; C Suri; K Smith; J McClain; T N Sato; G D Yancopoulos; D M McDonald
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

5.  Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis.

Authors:  K Koga; T Todaka; M Morioka; J Hamada ; Y Kai; S Yano; A Okamura; N Takakura; T Suda; Y Ushio
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

6.  Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions.

Authors:  J R Gamble; J Drew; L Trezise; A Underwood; M Parsons; L Kasminkas; J Rudge; G Yancopoulos; M A Vadas
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

7.  Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway.

Authors:  I Kim; J H Kim; S O Moon; H J Kwak; N G Kim; G Y Koh
Journal:  Oncogene       Date:  2000-09-14       Impact factor: 9.867

8.  Changes in tumor hypoxia measured with a double hypoxic marker technique.

Authors:  A S Ljungkvist; J Bussink; P F Rijken; J A Raleigh; J Denekamp; A J Van Der Kogel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-12-01       Impact factor: 7.038

9.  A neurovascular niche for neurogenesis after stroke.

Authors:  John J Ohab; Sheila Fleming; Armin Blesch; S Thomas Carmichael
Journal:  J Neurosci       Date:  2006-12-13       Impact factor: 6.167

10.  Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo.

Authors:  Ivan B Lobov; Peter C Brooks; Richard A Lang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-05       Impact factor: 11.205

View more
  7 in total

1.  Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.

Authors:  Sung-Suk Chae; Walid S Kamoun; Christian T Farrar; Nathaniel D Kirkpatrick; Elisabeth Niemeyer; Annemarie M A de Graaf; A Gregory Sorensen; Lance L Munn; Rakesh K Jain; Dai Fukumura
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

2.  ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery.

Authors:  Haochen Xu; Yongliang Cao; Xing Yang; Ping Cai; Lijing Kang; Ximin Zhu; Haiyu Luo; Lu Lu; Lixiang Wei; Xiaofei Bai; Yuanbo Zhu; Bing-Qiao Zhao; Wenying Fan
Journal:  Blood       Date:  2017-04-20       Impact factor: 22.113

3.  Chronic arterial hypertension impedes glioma growth: a multiparametric MRI study in the rat.

Authors:  Annelise Letourneur; Simon Roussel; Myriam Bernaudin; Fabien Fillesoye; Jérôme Toutain; Eric T MacKenzie; Edwige Petit; Omar Touzani; Samuel Valable
Journal:  Hypertens Res       Date:  2015-06-18       Impact factor: 3.872

4.  Angiopoietin-2 is vasoprotective in the acute phase of cerebral ischemia.

Authors:  Léna Marteau; Samuel Valable; Didier Divoux; Simon A Roussel; Omar Touzani; Eric T MacKenzie; Myriam Bernaudin; Edwige Petit
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-05       Impact factor: 6.200

5.  Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.

Authors:  Aurélien Corroyer-Dulmont; Elodie A Pérès; Edwige Petit; Jean-Sébastien Guillamo; Nathalie Varoqueaux; Simon Roussel; Jérôme Toutain; Didier Divoux; Eric T MacKenzie; Jérôme Delamare; Méziane Ibazizène; Myriam Lecocq; Andréas H Jacobs; Louisa Barré; Myriam Bernaudin; Samuel Valable
Journal:  Neuro Oncol       Date:  2012-10-31       Impact factor: 12.300

6.  Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma.

Authors:  Aurélien Corroyer-Dulmont; Elodie A Pérès; Aurélie N Gérault; Ariel Savina; Fanny Bouquet; Didier Divoux; Jérôme Toutain; Méziane Ibazizène; Eric T MacKenzie; Louisa Barré; Myriam Bernaudin; Edwige Petit; Samuel Valable
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-05       Impact factor: 9.236

7.  Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models.

Authors:  Ashley M Stokes; Charles P Hart; C Chad Quarles
Journal:  Tomography       Date:  2016-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.